<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35596222</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>20</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>Effective protection of ZF2001 against the SARS-CoV-2 Delta variant in lethal K18-hACE2 mice.</ArticleTitle><Pagination><StartPage>86</StartPage><MedlinePgn>86</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">86</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12985-022-01818-x</ELocationID><Abstract><AbstractText>To investigate the protective efficacy and mechanism of ZF2001 (a protein subunit vaccine with conditional approval in China) to SARS-CoV-2 Delta variant-induced severe pneumonia, the lethal challenge model of K18-hACE2 transgenic mice was used in this study. An inactivated-virus vaccine at the research and development stage (abbreviated as RDINA) was compared to ZF2001. We found that ZF2001 and RDINA could provide the protective effect against Delta variant-induced severe cases, as measured by the improved survival rates, the reduced virus loads, the alleviated lung histopathology and the high neutralizing antibody geomean titers, compared to aluminum adjuvant group. To prevent and control Omicron or other variant epidemics, further improvements in vaccine design and compatibilities with the novel adjuvant are required to achieve better immunogenicity.</AbstractText><CopyrightInformation>Â© 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Bian</LastName><ForeName>Lianlian</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, and NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Bai</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, and NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, and NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Mingchen</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, and NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, and NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, and NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, and NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Miao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, and NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China. xumiaobj@126.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, and NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing, China. lzhenglun@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C045927">K-18 conjugate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005719">gamma-Globulins</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q41OR9510P</RegistryNumber><NameOfSubstance UI="D008558">Melphalan</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008558" MajorTopicYN="N">Melphalan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005719" MajorTopicYN="N">gamma-Globulins</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">K18-hACE2 mice</Keyword><Keyword MajorTopicYN="N">Protection</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2 Delta variant</Keyword><Keyword MajorTopicYN="N">ZF2001</Keyword></KeywordList><CoiStatement>All authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>20</Day><Hour>23</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35596222</ArticleId><ArticleId IdType="pmc">PMC9122244</ArticleId><ArticleId IdType="doi">10.1186/s12985-022-01818-x</ArticleId><ArticleId IdType="pii">10.1186/s12985-022-01818-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. COVID-19 weekly epidemiological update. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---1-february-2022.</Citation></Reference><Reference><Citation>COVID-19 vaccine tracker and landscape. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.</Citation></Reference><Reference><Citation>COVID-19 vaccine tracker. https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-vaccine-tracker.</Citation></Reference><Reference><Citation>Zifivax (ZF2001) COVID-19 vaccine. https://www.precisionvaccinations.com/vaccines/zifivax-zf2001-covid-19-vaccine.</Citation></Reference><Reference><Citation>Organization World Health. The COVID-19 vaccine tracker and landscape compiles detailed information of each COVID-19 vaccine candidate in development by closely monitoring their progress through the pipeline. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.</Citation></Reference><Reference><Citation>Mlcochova P, et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature. 2021;599(7883):114â119. doi: 10.1038/s41586-021-03944-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03944-y</ArticleId><ArticleId IdType="pmc">PMC8566220</ArticleId><ArticleId IdType="pubmed">34488225</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong W, et al. The K18-human ACE2 transgenic mouse model recapitulates non-severe and severe COVID-19 in response to an infectious dose of the SARS-CoV-2 virus. J Virol. 2022;96(1):e0096421. doi: 10.1128/JVI.00964-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00964-21</ArticleId><ArticleId IdType="pmc">PMC8754221</ArticleId><ArticleId IdType="pubmed">34668775</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, et al. Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein. Signal Trans Target Ther. 2021 doi: 10.1038/s41392-021-00797-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00797-9</ArticleId><ArticleId IdType="pmc">PMC8578532</ArticleId><ArticleId IdType="pubmed">34759261</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler ES, et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat Immunol. 2020;21(11):1327â1335. doi: 10.1038/s41590-020-0778-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0778-2</ArticleId><ArticleId IdType="pmc">PMC7578095</ArticleId><ArticleId IdType="pubmed">32839612</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang JK, et al. Lung morphometry changes in prevention of airway remodeling by protocatechuic aldehyde in asthmatic mice. Int J Clin Exp Med. 2015;8(5):528.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4509171</ArticleId><ArticleId IdType="pubmed">26221226</ArticleId></ArticleIdList></Reference><Reference><Citation>He Q, et al. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg Microbes Infect. 2021;10(1):629â637. doi: 10.1080/22221751.2021.1902245.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.1902245</ArticleId><ArticleId IdType="pmc">PMC8009122</ArticleId><ArticleId IdType="pubmed">33691606</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, et al. Pathological changes in the lungs and lymphatic organs of 12 COVID-19 autopsy cases. Natl Sci Rev. 2020;7(12):1868â1878. doi: 10.1093/nsr/nwaa247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nsr/nwaa247</ArticleId><ArticleId IdType="pmc">PMC7543449</ArticleId><ArticleId IdType="pubmed">34676085</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury DS, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205â1211. doi: 10.1038/s41591-021-01377-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01377-8</ArticleId><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Zang J, et al. Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection. Cell Discov. 2021;7(1):71. doi: 10.1038/s41421-021-00315-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-021-00315-9</ArticleId><ArticleId IdType="pmc">PMC8372230</ArticleId><ArticleId IdType="pubmed">34408130</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W, et al. The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice. Signal Transduct Target Ther. 2021;6(1):340. doi: 10.1038/s41392-021-00750-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00750-w</ArticleId><ArticleId IdType="pmc">PMC8426336</ArticleId><ArticleId IdType="pubmed">34504054</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao M, et al. Broad-spectrum anti-coronavirus vaccines and therapeutics to combat the current COVID-19 pandemic and future coronavirus disease outbreaks. Stem Cell Rep. 2021;16(3):398â411. doi: 10.1016/j.stemcr.2020.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2020.12.010</ArticleId><ArticleId IdType="pmc">PMC7940144</ArticleId><ArticleId IdType="pubmed">33691145</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinnakasu R, et al. Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses. J Exp Med. 2021;218(12):e20211003. doi: 10.1084/jem.20211003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20211003</ArticleId><ArticleId IdType="pmc">PMC8641255</ArticleId><ArticleId IdType="pubmed">34623376</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>